40 results about "Dexibuprofen" patented technology

The invention discloses a nalorphine amino compound and preparing method with structural formula as (I), wherein the amino can be Arg, Lys or His; the molecular rate of nalorphine and amino is 1:1-1: 5 or 5:1-1:1.

The invention discloses a dexibuprofen slow-release capsule. Pellets are filled in the capsule, each pellet consists of a pellet core and four layers of materials wrapped outside the pellet core, the four layers of materials are sequentially an inner isolation layer, a first coating layer, a second coating layer and a third coating layer from inside to outside, and the pellet core, the inner isolation layer, the first coating layer, the second coating layer and the third coating layer respectively have the following compositions: the pellet core is prepared by medicine auxiliary materials, the inner isolation layer is stearic acid, the first coating layer is a coating mixture, the second coating layer comprises the coating mixture and the stearic acid, the third coating layer is the coating mixture, and the coating mixture consists of dexibuprofen and polyvidone K30. The invention also provides a production method of the dexibuprofen slow-release capsule. Compared with an ordinary capsule, the dexibuprofen slow-release capsule disclosed by the invention has the same absorption degree, but the dexibuprofen blood maximum concentration (Cmax) of the dexibuprofen slow-release capsule disclosed by the invention in human bodies is lower, the maximum time (Tmax) from the administration to the blood Cmax reaching is longer, and a good slow release effect is realized.

The invention provides a dexibuprofen medical composition that can improve dissolution and a preparation method thereof, relating to the method technology field that improves the dissolution rate of the dexibuprofen medical compositions which comprise amino acid, sodium carbonate and sodium bicarbonate, being added with proper amount of other pharmaceutic adjuvant to form a new dexibuprofen medical composition. The dexibuprofen medical composition added with solubilization composition can be dissolved quickly in vivo and in vitro to shorten the absorption time and to improve the bioavailability of the blood plasma, thus resisting disease more quickly and effectively.

Stable non-alcoholic transdermal hydrogel of dexibuprofen was prepared by using a simple manufacturing process, and the experimental trials showed that the pH modifying agent, antioxidant and water miscible solvent are the essential excipients to obtain stable non-alcoholic transdermal hydrogel of dexibuprofen. The dexibuprofen hydrogel prepared using carbopol as a gelling polymer produced an opaque gel, whereas hydrogel prepared using hyroxypropyl methylcellulose (HPMC) as a gelling polymer produced a transparent gel. There was no significant changes observed with respect to physical description, pH, assay and particularly to the related substance values when the hydrogels were subjected to the stability study at accelerated condition (40 DEG C / 75% RH) for 3 months in laminated tubes.

The invention discloses a dexibuprofen amino acid salt injection and a preparation method thereof. The method is characterized by taking sodium bicarbonate as an adjuvant of the preparation to provide stable quality, less irritability and no hematolysis to the injection. The injection is mainly used for allaying a fever, easing the pain and resisting inflammation when oral administration is not suitable or is forbidden.

The invention discloses a preparation method of dexibuprofen amino acid salt. The method is characterized by adding amino acid to dexibuprofen ethanol solution while stirring at room temperature, and completing salt forming and crystallization in turn in a container, and the method has the advantages of simple and convenient preparation process, short production period, low impurity level, high yield and good reproducibility. The dexibuprofen amino acid salt can be used for preparing oral solution preparation, also can be used for preparing injection preparation, accelerates absorption rate, enhances bioavailability and enlarges application range.

The invention belongs to the field of medical technology, and discloses emulsion injection taking dexibuprofen as a raw material and a preparation method of the emulsion injection. The emulsion injection is characterized in that each 1 L of the emulsion injection comprises the following components by mass: 30 to 100 g of dexibuprofen, 100 to 250 g of soybean oil, 9 to 24 g of phospholipid, 2 to 6 g of oleinic acid, 1 to 16 g of poloxamer, 20 to 25 g of glycerol, pH adjusting ingredients, and the balance of water for injection. The emulsion injection adopts the emulsification technology, and takes an oil-water surface as a film to carry medicine, so as to solve the problem that as dexibuprofen is difficult to dissolve in water, and improve the drug loading capacity; compared with other preparations, the emulsion injection is lower in adverse reaction and toxic side effects, higher in bioavailability, lower in preparation cost, and more convenient to use by patients.

The invention provides a dexibuprofen injection composition which comprises dexibuprofen, arginine and water for injection, wherein other regulating agents and organic solvents do not need to be added; the dexibuprofen can be fully dissolved to form a stable medicament composition by regulating the ratio of the arginine to the dexibuprofen. The dexibuprofen injection composition provided by the invention is higher in stability; the pH of the injection is in a blood tolerance range of a human body, so that a requirement on clinical medication can be met.

The invention discloses a preparation method of an arginine dexibuprofen raw medicine. The method comprises the steps of: dissolving dexibuprofen in ethanol, heating the mixture to a temperature of 50DEG C-60DEG C, adding L-arginine in a dropwise manner slowly and continuously under stirring within 10min-20min, continuing stirring for reaction for 2h-3.5h with the temperature maintained at 50DEG C-60DEG C, leaving the mixture to stand for 25min-35min and cool to a temperature of 18DEG C-30DEG C, conducting pumping filtration so as to obtain crystals, then washing and drying the crystals, thus obtaining white crystals, i.e. arginine dexibuprofen. The preparation method of the invention has simple process, high yield, no refining step, shortened production period, and no need for any special equipment, thus being suitable for industrial production.

The present invention relates to a use of a dexibuprofen levocetirizine double-layer sustained release tablet in treatment of airway inflammation. The tablet is composed of two layers, wherein one layer is the rapid-release part, composed of dexibuprofen, levocetirizine dihydrochloride and a pharmaceutically acceptable rapid-release additive; the other layer is the sustained-release part, composed of dexibuprofen and a pharmaceutically acceptable sustained-release additive.

The invention discloses a method for determining a dexibuprofen related matter. According to the method, a high performance liquid chromatography method is adopted for simultaneously determining and checking 17 related impurities, such as, impurity A, impurity B, impurity C, and the like, possible to appear in dexibuprofen bulk drug. The method is time-saving, labor-saving and high in precision. Through verification, the method can be used for conventional analysis and quality control for the dexibuprofen raw material and the preparation sample.

The invention relates to a dexibuprofen purifying method. The method comprises the following steps: dissolving crude dexibuprofen in an organic solvent 1, adding a sodium hydroxide solution in a dropwise manner to adjust the pH value to 9-10, carrying out cooling crystallization to obtain dexibuprofen sodium; dissolving dexibuprofen sodium in purified water, adding an organic solvent 2, and adding hydrochloric acid in a dropwise manner under stirring in order to adjust the pH value to 1-2; and carrying out liquid separation, taking the obtained organic phase, and carrying out reduced pressure distillation on the organic phase to obtain a solid which is purified dexibuprofen. The product obtained through the method has high purity of above 99.7% and high yield of above 75%; the method can completely eliminate ibuprofen ester impurities, and allows the maximal content of single impurities to be smaller than 0.1% and the total content of the impurities to be smaller than 0.3%; and the method has the advantages of low cost, simplicity and easy control of process steps, and suitableness for large scale production.

The invention discloses a pharmaceutical preparation used for resisting inflammation, alleviating pain and eliminating fever, and particularly relates to a prepared sustained-release oral formulation adopting dexibuprofen as the ingredient. The pharmaceutical preparation aims to supplement the deficiency of the prior art and provide a sustained-release dexibuprofen dropping pill. The sustained-release dexibuprofen dropping pill overcomes the defects in the prior art effectively, guarantees no occurrence of an obvious quality change for the drug during the effective storage period and has the advantages of controllable release time, full release and high bioavailability simultaneously.

The invention discloses a dexibuprofen particle which is mainly prepared from the following raw materials in parts by weight: 1-10 parts of dexibuprofen, 1-6 parts of sodium carbonate, 1-35 parts of sucrose, 0.1-0.8 part of aspartame and 3-12 parts of ethanol. The invention also discloses a preparation method of the dexibuprofen particle, which comprises the following steps of: sieving each raw material, and then, fully mixing the raw materials uniformly; granulating; and drying at high temperature, and then, refining to obtain the dexibuprofen particle. The dexibuprofen particle of the invention can endure high-temperature drying, has qualified indexes of microbial limit, solubility and the like and has stable and controllable quality; in addition, the preparation method is simple to operate has short production cycle and low cost, and is suitable for industrialized production.

The invention provides a preparation method of a dexibuprofen injection. The method prepares dexibuprofen and appropriate auxiliary materials into a dexibuprofen injection with stable and controllable quality. The dexibuprofen injection relieves pain and fever of inpatients unable to employ oral administration, also has the advantages of avoidance of first pass effect and gastrointestinal reaction of drugs, quick effect, and good stability, etc.

The invention relates to dexibuprofen microemulsion gel and a preparation method thereof. The dexibuprofen microemulsion gel comprises components including dexibuprofen, a surfactant, a cosurfactant, an oil phase, carbomer and water. The dexibuprofen microemulsion gel is subjected to colon-drip delivery, the drug takes a microemulsion as a supporter, the drug solubility is increased, besides, the dexibuprofen microemulsion gel has proper flexibility and biological adhesion, a patient has a week foreign body sensation, the gel cannot flow out of the rectum easily after delivery, and absorption of the drug is facilitated, so that the better efficacy is guaranteed.

The invention relates to a dexibuprofen enteric-coated and sustained-release tablet. The dexibuprofen enteric-coated and sustained-release tablet comprises a tablet core with a sustained release effect and a coating for coating the table core, wherein the tablet core is prepared from the following components: 70-90 parts of dexibuprofen, 10-30 parts of sustained-release skeleton stabilizer, 0-10 parts of filler, 0.2-1.5 parts of lubricating agent and 0.2-1.5 parts of flow aid; the effective quantity of active ingredient dexibuprofen takes more than 70% of the weight of table core. The invention has the advantages of excellent formula, reliable preparation process and easiness in industrial production; the prepared enteric-coated and sustained-release tablet in-vitro dissolution experiment shows: the releasing rate of gastric juice in 2 hours is smaller than 10%, which meets the requirements; the releasing rate of intestinal juice in 2 hours is 25-55%, the accumulative releasing rate in 4 hours is 50-80%, the accumulative releasing rate in 8 hours is more than 80%, and therefore, the releasing effect is excellent. The dexibuprofen enteric-coated and sustained-release tablet has effects of undissolving in the stomach and slowly releasing in the intestines so as to prevent irritation to the stomach and prolong the in-vivo releasing time of medicines simultaneously; the dexibuprofen enteric-coated and sustained-release tablet facilitates absorption to human bodies and has lasting effects.

The invention relates to a preparation method of a dexibuprofen lipid emulsion injection. The preparation method comprises the following steps that long-chain fatty acid, medium-chain fatty acid and KolliphorHS 15 are heated and stirred to form a homogeneous oil-phase solution; an emulsifier, an osmotic pressure regulating agent and water are evenly mixed to form a water-phase solution; the oil phase and the water phase are mixed, stirred at a certain temperature, sheared and emulsified, and after high-pressure homogenization, pH regulating, filtration, sterilization and the like, the dexibuprofen lipid emulsion injection is obtained. The novel solubilizer KolliphorHS 15 for injection is adopted, the problems about the compatible stability and the drug loading capacity of a dexibuprofen injection during clinical use are effectively solved, and the safety of a preparation is expected to be improved.

The invention discloses dexibuprofen particles and a preparation method thereof. According to the invention, appropriate auxiliary materials are combined with dexibuprofen, such that dexibuprofen is subject to self-emulsification in gastrointestinal tracts, and is maintained an emulsion. Compared with common dexibuprofen preparations, the dexibuprofen particles provided by the invention has advantages of good dissolution rate, high absorption speed, good controllability of preparation technological quality, good stability, and the like. The invention provides a dexibuprofen preparation with higher security, better curative effect, simpler preparation technology and good stability.

The invention discloses new medical salt of dexibuprofen. According to the salt, x can be 0, 0.5, 1, 1.5, 2, 2.5 and 3, n can be 1, 2, and 3, and M can be sodium, potassium, magnesium, zinc, arginine and lysine. The invention provides a preparation method of the salt, and also a medicine composite containing the salt. The composite contains a carrier which can be accepted by medicines; and the medicine composite can be produced in an appropriate and medical dosage form during the producing of medicaments.

The invention relates to a dexibuprofen liposome as well as a reparation method and application thereof. The dexibuprofen liposome is prepared from the following components in percentage by mass: 1.0to 10.0 percent of dexibuprofen, 3.0 to 8.0 percent of phospholipid, 0.5 to 5.0 percent of cholesterol, 1.0 to 10.0 percent of diethylene glycol monoethyl ether, 0.5 to 5.0 percent of vitamin E polyethylene glycol succinate, 10.0 to 30.0 percent of polylol, 0.1 to 0.2 percent of citric acid and the balance of purified water. An oil phase prepared from the dexibuprofen, the phospholipid, the cholesterol and the diethylene glycol monoethyl ether is dropwise added into a water phase prepared from the vitamin E polyethylene glycol succinate, the polylol, the citric acid and the purified water, andthen an obtained mixture is treated through a high-speed shearing emulsification, high-pressure homogenization or high-pressure micro jet device, and the dexibuprofen liposome prepared by the preparation method is high in drug loading capacity, can be used for promoting the dexibuprofen to penetrate through a skin and retain for a long time in a high-concentration manner, and meanwhile, has favorable stability and safety.

The invention relates to a preparation method of a dexibuprofen sustained-release agent, and aims to overcome the medical treatment and preparation defects of dexibuprofen medicine. The preparation method comprises the following steps: taking montmorillonite, hydrochloric acid, absolute ethanol and deionized water as raw materials; modifying the montmorillonite; preparing an aqueous hydrochloric acid solution and montmorillonite mixed liquor; performing ultrasonic dispersion, centrifugal separation, vacuum freeze drying, grinding and sieving to prepare dexibuprofen sustained-release agent powder particles, wherein the particle diameters of the particles are smaller than or equal to 200nm, and the product purity is up to 99.6 percent. The preparation method has the advantages of advanced process, accurate and complete data, short process flow and freeness from environmental pollution, and is an advanced method for preparing the dexibuprofen sustained-release agent; the dexibuprofen sustained-release agent can be applied to clinical medication in the department of pediatrics.

The invention discloses a pharmaceutical composition of dexibuprofen and its medical use. The pharmaceutical composition of dexibuprofen provided by the invention contains dexibuprofen and a natural product compound (I) with a novel structure. When dexibuprofen and compound (I) act alone, they have a therapeutic effect on glomerulonephritis; when dexibuprofen and compound (I) act in combination, the therapeutic effect is further improved, and can be developed into a drug for treating glomerulonephritis , compared with the prior art, has outstanding substantive features and remarkable progress.

The invention relates to a slow-release dry dexibuprofen suspension. The slow-release dry dexibuprofen suspension comprises slow-release dexibuprofen pellets, dilute particles and auxiliary materials,wherein each slow-release dexibuprofen pellet comprises a blank pellet core, a medicine-carrying layer and a slow-release layer; each dilute particle comprises a surfactant, a first filler, a flavoring agent and a preservative; the auxiliary materials include a second filler, a suspending aid, a first anti-adhesive agent, a flow aid and an essence; based on the total weight of the slow-release dry dexibuprofen suspension, the slow-release dry dexibuprofen suspension comprises the following components in percent by weight: 10-15% of the slow-release dexibuprofen pellets, 0.2-0.5% of the surfactant, 65-85% of the first filler and the second filler together, 2-7% of the flavoring agent, 0.5-3% of the suspending aid, 0.5-3% of the preservative, 0.5-3% of the first anti-adhesive agent, 0.5-3%of the flow aid and 0.1-2% of the essence. The slow-release dry dexibuprofen suspension provided by the invention has a relatively good slow-release effect and relatively good preparation stability, so that the number of medications is reduced and the medication compliance of a patient is improved.